New diabetes drug DA-5218 aims to help when metformin Isn't enough
NCT ID NCT07229534
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called DA-5218 in 238 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone. Participants will receive either DA-5218 or an active comparator, and researchers will measure changes in HbA1c over time. The trial is double-blind and randomized, meaning neither patients nor doctors know who gets which treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DA-5218 (an experimental diabetes drug)
What this could lead to
If successful, DA-5218 could offer a new treatment option for people with type 2 diabetes who need better blood sugar control despite taking metformin.
What could go wrong
This is a Phase IV trial, so the drug is already approved in some form, but it may still have side effects or not work better than existing options. Results are limited to short-term blood sugar changes, not long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.